The Transcriptome Landscape of the In Vitro Human Airway Epithelium Response to SARS-CoV-2

Int J Mol Sci. 2023 Jul 27;24(15):12017. doi: 10.3390/ijms241512017.

Abstract

Airway-liquid interface cultures of primary epithelial cells and of induced pluripotent stem-cell-derived airway epithelial cells (ALI and iALI, respectively) are physiologically relevant models for respiratory virus infection studies because they can mimic the in vivo human bronchial epithelium. Here, we investigated gene expression profiles in human airway cultures (ALI and iALI models), infected or not with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), using our own and publicly available bulk and single-cell transcriptome datasets. SARS-CoV-2 infection significantly increased the expression of interferon-stimulated genes (IFI44, IFIT1, IFIT3, IFI35, IRF9, MX1, OAS1, OAS3 and ISG15) and inflammatory genes (NFKBIA, CSF1, FOSL1, IL32 and CXCL10) by day 4 post-infection, indicating activation of the interferon and immune responses to the virus. Extracellular matrix genes (ITGB6, ITGB1 and GJA1) were also altered in infected cells. Single-cell RNA sequencing data revealed that SARS-CoV-2 infection damaged the respiratory epithelium, particularly mature ciliated cells. The expression of genes encoding intercellular communication and adhesion proteins was also deregulated, suggesting a mechanism to promote shedding of infected epithelial cells. These data demonstrate that ALI/iALI models help to explain the airway epithelium response to SARS-CoV-2 infection and are a key tool for developing COVID-19 treatments.

Keywords: SARS-CoV-2 signatures; airway in vitro models; iPS cells; transcriptomic analysis.

MeSH terms

  • COVID-19* / genetics
  • Epithelial Cells
  • Epithelium
  • Humans
  • Interferons / genetics
  • Respiratory Mucosa
  • SARS-CoV-2*
  • Transcriptome

Substances

  • Interferons

Grants and funding

Supported by grants from the University Hospital of Montpellier (Appel d’offre interne, projet CILIPS 9174, projet INVECCO 9791), the association Vaincre la Mucoviscidose (Grant #RIF20170502048), the Fondation pour la Recherche Médicale (Grant #FDM20170638083), the Labex Numev (ANR-10-LAB-20), and Astrazenca. The acquisition of the Cell-Discoverer 7 LSM900 microscope was funded by FEDER-FSE Région Occitanie throughout the MIP-FISH project. Part of this research project was supported by the CNRS INSB funding through the VIROCRIB program.